Skip to main content
SpringerLink
Log in

Direct thrombin inhibitors

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Direct thrombin inhibitors (DTIs) are a new class of therapeutics possessing theoretic advantages over unfractionated heparin (UFH). In contrast to UFH, DTIs do not activate platelets, have no circulating inhibitors, and bind to both free and clot-bound thrombin. These theoretical advantages have spurred clinical trials investigating DTIs in a variety of cardiovascular indications. Currently, the major role for DTIs in cardiology is as an adjunct during percutaneous coronary intervention (PCI). Such a role stems from the results of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 randomized trial, in which bivalirudin with provisional abciximab was demonstrated to be equivalent to UFH plus planned abciximab with respect to ischemic endpoints, while being associated with less bleeding. Ongoing clinical trials will define the role of bivalirudin as an adjunct to primary PCI for ST-segment elevation myocardial infarction and in non-ST segment elevation acute coronary syndrome as an adjunct to an early invasive strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Serruys PW, Herrman JP, Simon R, et al.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995, 333:757–763.

    Article  PubMed  CAS  Google Scholar 

  2. Bittl JA, Strony J, Brinker JA, et al.: Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995, 333:764–769.

    Article  PubMed  CAS  Google Scholar 

  3. Bittl JA, Chaitman BR, Feit F, et al.: Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001, 142:952–959.

    Article  PubMed  CAS  Google Scholar 

  4. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al.: Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002, 143:847–853.

    Article  PubMed  CAS  Google Scholar 

  5. Lincoff AM, Bittl JA, Kleiman NS, et al.: Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004, 93:1092–1096.

    Article  PubMed  CAS  Google Scholar 

  6. Lincoff AM, Bittl JA, Harrington RA, et al.: Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003, 289:853–863. This landmark trial definitively demonstrated the equivalence of bivalirudin with provisional abciximab as compared with UFH with planned abciximab during PCI. Bivalirudin was also associated with less bleeding.

    Article  PubMed  CAS  Google Scholar 

  7. Lincoff AM, Kleiman NS, Kereiakes DJ, et al.: Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004, 292:696–703. This analysis of REPLACE-2 demonstrated the long-term equivalence of bivalirudin as compared with UFH with GP IIb/IIIa inhibitors during PCI.

    Article  PubMed  CAS  Google Scholar 

  8. Cohen DJ, Lincoff AM, Lavelle TA, et al.: Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 2004, 44:1792–1800.

    PubMed  CAS  Google Scholar 

  9. Dangas GD, Lasic Z, Mehran R, et al.: Bivalirudin is a safe replacement to heparin during percutaneous coronary intervention with drug-eluting stents: final results of the multicenter ADEST study. Am J Cardiol 2004, 94(Suppl 6A):37E.

    Google Scholar 

  10. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 1996, 335:775–782.

  11. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 1999, 353:429–438.

  12. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002, 359:294–302. This meta-analysis of 35,970 patients from 11 randomized trials provides the most comprehensive analysis of DTIs in ACS.

  13. Cannon CP, Weintraub WS, Demopoulos LA, et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/ IIIa inhibitor tirofiban. N Engl J Med 2001, 344:1879–1887.

    Article  PubMed  CAS  Google Scholar 

  14. Comparison of angiomax versus heparin in acute coronary syndromes. http://www.clinicaltrials.gov/ct/gui/show/ NCT00093158

  15. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation 1994, 90:1631–1637.

  16. Neuhaus KL, von Essen R, Tebbe U, et al.: Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 1994, 90:1638–1642.

    PubMed  CAS  Google Scholar 

  17. Antman EM: Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994, 90:1624–1630.

    PubMed  CAS  Google Scholar 

  18. Antman EM: Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996, 94:911–921.

    PubMed  CAS  Google Scholar 

  19. White H: Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001, 358:1855–1863. This large randomized trial assessed the efficacy and safety of bivalirudin as an adjunct to thrombolytics in STEMI.

    Article  PubMed  CAS  Google Scholar 

  20. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13–20.

    Article  PubMed  Google Scholar 

  21. Cardiovascular Research Foundation News. http://www.crf.org/news.html

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F25, 44195, Cleveland, OH, USA

    A. Michael Lincoff MD

Authors
  1. Michael S. Chen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Michael Lincoff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, M.S., Lincoff, A.M. Direct thrombin inhibitors. Curr Cardiol Rep 7, 255–259 (2005). https://doi.org/10.1007/s11886-005-0046-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-005-0046-y

Keywords

Search

Navigation